Literature DB >> 21926475

LSD1 and pluripotency: a new player in the network.

Antonio Adamo, Maria J Barrero, Juan Carlos Izpisua Belmonte.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21926475     DOI： 10.4161/cc.10.19.17052

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  9 in total

1.  GATA-1 utilizes Ikaros and polycomb repressive complex 2 to suppress Hes1 and to promote erythropoiesis.

Authors:  Julie Ross; Lionel Mavoungou; Emery H Bresnick; Eric Milot
Journal:  Mol Cell Biol       Date:  2012-07-09       Impact factor: 4.272

2.  New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.

Authors:  Nam Hoang; Xuan Zhang; Chunxiao Zhang; Van Vo; Feng Leng; Lovely Saxena; Feng Yin; Fei Lu; Guangrong Zheng; Pradip Bhowmik; Hui Zhang
Journal:  Bioorg Med Chem       Date:  2018-02-07       Impact factor: 3.641

3.  Differential responses to retinoic acid and endocrine disruptor compounds of subpopulations within human embryonic stem cell lines.

Authors:  Lois A Annab; Carl D Bortner; Marie I Sifre; Jennifer M Collins; Ruchir R Shah; Darlene Dixon; H Karimi Kinyamu; Trevor K Archer
Journal:  Differentiation       Date:  2012-08-18       Impact factor: 3.880

4.  Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma.

Authors:  Stefano Amente; Giorgio Milazzo; Maria Cristina Sorrentino; Susanna Ambrosio; Giacomo Di Palo; Luigi Lania; Giovanni Perini; Barbara Majello
Journal:  Oncotarget       Date:  2015-06-10

5.  The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.

Authors:  Kristian W Pajtler; Christina Weingarten; Theresa Thor; Annette Künkele; Lukas C Heukamp; Reinhard Büttner; Takayoshi Suzuki; Naoki Miyata; Michael Grotzer; Anja Rieb; Annika Sprüssel; Angelika Eggert; Alexander Schramm; Johannes H Schulte
Journal:  Acta Neuropathol Commun       Date:  2013-05-29       Impact factor: 7.801

Review 6.  KDM1A microenvironment, its oncogenic potential, and therapeutic significance.

Authors:  Tayaba Ismail; Hyun-Kyung Lee; Chowon Kim; Taejoon Kwon; Tae Joo Park; Hyun-Shik Lee
Journal:  Epigenetics Chromatin       Date:  2018-06-19       Impact factor: 4.954

Review 7.  SIRT1 in the Development and Treatment of Hepatocellular Carcinoma.

Authors:  Marius Farcas; Andrei-Alexandru Gavrea; Diana Gulei; Calin Ionescu; Alexandru Irimie; Cristina S Catana; Ioana Berindan-Neagoe
Journal:  Front Nutr       Date:  2019-09-25

8.  Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells.

Authors:  Jianwu Fang; Haiyan Ying; Ting Mao; Yanjia Fang; Yuan Lu; He Wang; Irene Zang; Zhaofu Wang; Ying Lin; Mengxi Zhao; Xiao Luo; Zongyao Wang; Yan Zhang; Chao Zhang; Wei Xiao; Yan Wang; Wei Tan; Zhui Chen; Chris Lu; Peter Atadja; En Li; Kehao Zhao; Jianfeng Liu; Justin Gu
Journal:  Oncotarget       Date:  2017-06-19

Review 9.  The Role of LSD1 and LSD2 in Cancers of the Gastrointestinal System: An Update.

Authors:  Gianluca Malagraba; Mahdieh Yarmohammadi; Aadil Javed; Carles Barceló; Teresa Rubio-Tomás
Journal:  Biomolecules       Date:  2022-03-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.